2160 (2160) Fair Value & Analysis
Healthcare · Market cap HK$1.5B
Fair value as of: Jul 2, 2026
From 4 valuation models · updated today
Share price −30.4% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$1.07 – HK$8.10 · fair‑value band HK$0.3854 – HK$1.14 · the HK$1.17 price screens above the HK$0.7609 fair value. As of Jul 2, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
2160 (2160) currently trades at HK$1.17, while our model-based Fair Value estimate is HK$0.7609 — implying the stock looks roughly 35.0% overvalued today. We read business quality at 27/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, 2160 generated revenue of HK$57.0M at a net margin of -33.0%. Revenue grew 20.0% year over year. It earns a return on equity of -6.7%. Net debt stands at HK$1.3B. Fundamentals as of Jul 2, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
2160 reported revenue of HK$444M in FY2025 versus HK$201M in FY2021, a compound +21.9%/yr. Reported net income was −HK$146M in FY2025.
Is 2160 fairly valued? → Check now
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ABT ABT | 1,600 MXN | 1,228 MXN | -23% |
| Abbott Laboratories, ABTT34 | R$37.76 | R$6.34 | -83% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 2160 (2160) undervalued?
What is the fair value of 2160?
What is the quality score of 2160?
What is the revenue of 2160 (2160)?
What is the net profit margin of 2160?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.